ATAI Life Sciences NV
ATAI4.255USD
+0.085+2.04%
交易中 （美东）报价延迟15分钟
850.04M总市值
亏损市盈率 TTM
关于 ATAI Life Sciences NV 公司
ATAI Life Sciences NV 是一家总部位于德国的临床阶段生物制药公司。该公司致力于开发各种治疗方法，重点是各种精神健康障碍。该公司的治疗先导化合物包括 PCN-101，一种用于治疗难治性抑郁症 (TRD) 的 R-氯胺酮皮下制剂；RL-007，一种用于治疗与精神分裂症相关的认知障碍的胆碱能、谷氨酸能和 GABA-B 受体调节剂；DMX-1002，一种用于治疗阿片类药物使用障碍 (OUD) 的伊博格碱口服制剂；GRX-917，一种用于治疗广泛性焦虑症的氘代乙替福辛口服制剂；和 NN-101，一种用于治疗轻度创伤性脑损伤的新型 N-乙酰半胱氨酸鼻内制剂。其治疗候选药物还包括 VLS-01，一种用于治疗 TRD 的 N,N-二甲基色胺制剂； EMP-01 是一种 3,4-亚甲基二氧基甲基苯丙胺口服制剂，用于治疗创伤后应激障碍。
公司简介
公司代码ATAI
公司名称ATAI Life Sciences NV
上市日期Jun 18, 2021
CEODr. Srinivas Rao, M.D., Ph.D.
员工数量54
证券类型Ordinary Share
年结日Jun 18
公司地址Wallstrasse 16
城市BERLIN
上市交易所NASDAQ Global Market Consolidated
国家Germany
邮编10179
电话498921539035
网址https://atai.life/
公司代码ATAI
上市日期Jun 18, 2021
CEODr. Srinivas Rao, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Glenn Frank Short, Ph.D.
Dr. Glenn Frank Short, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
42.33K
+84.10%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Supervisory Director
Independent Supervisory Director
4.67K
--
Dr. Amir Kalali
Dr. Amir Kalali
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Kevin James Craig, M.D.
Dr. Kevin James Craig, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Anne Johnson
Ms. Anne Johnson
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Gerd G. Kochendoerfer
Dr. Gerd G. Kochendoerfer
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Christian Angermayer
Mr. Christian Angermayer
Chairman of the Supervisory Board
Chairman of the Supervisory Board
--
--
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Srinivas Rao, M.D., Ph.D.
Dr. Srinivas Rao, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Interim Managing Director
Chief Executive Officer, Co-Founder, Interim Managing Director
--
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
Independent Supervisory Director
Independent Supervisory Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Glenn Frank Short, Ph.D.
Dr. Glenn Frank Short, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
42.33K
+84.10%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Supervisory Director
Independent Supervisory Director
4.67K
--
Dr. Amir Kalali
Dr. Amir Kalali
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Kevin James Craig, M.D.
Dr. Kevin James Craig, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Anne Johnson
Ms. Anne Johnson
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Gerd G. Kochendoerfer
Dr. Gerd G. Kochendoerfer
Chief Operating Officer
Chief Operating Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月23日 周五
更新时间: 5月23日 周五
持股股东
股东类型
持股股东
持股股东
占比
Apeiron Investment Group Ltd
20.82%
Galaxy Group Investments LLC
5.09%
Brand (Florian Olaf)
2.49%
UBS Financial Services, Inc.
1.82%
Pale Fire Capital SE
1.22%
Other
68.55%
持股股东
持股股东
占比
Apeiron Investment Group Ltd
20.82%
Galaxy Group Investments LLC
5.09%
Brand (Florian Olaf)
2.49%
UBS Financial Services, Inc.
1.82%
Pale Fire Capital SE
1.22%
Other
68.55%
股东类型
持股股东
占比
Family Office
20.82%
Corporation
5.09%
Investment Advisor
3.21%
Individual Investor
2.69%
Hedge Fund
2.54%
Investment Advisor/Hedge Fund
1.53%
Private Equity
1.22%
Research Firm
0.93%
Bank and Trust
0.79%
Other
61.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
222
39.10M
18.43%
+1.36M
2025Q1
234
37.63M
19.33%
-4.75M
2024Q4
244
63.86M
38.26%
-6.63M
2024Q3
245
61.76M
37.01%
-13.54M
2024Q2
256
62.32M
37.36%
-12.46M
2024Q1
254
62.51M
37.65%
-12.46M
2023Q4
261
63.36M
38.17%
-12.44M
2023Q3
269
64.07M
38.62%
-13.64M
2023Q2
274
64.60M
38.94%
-13.71M
2023Q1
265
65.17M
39.52%
-15.34M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Apeiron Investment Group Ltd
44.17M
20.82%
+1.80M
+4.25%
Jun 02, 2025
Galaxy Group Investments LLC
10.80M
5.09%
+2.33M
+27.44%
Apr 02, 2025
Brand (Florian Olaf)
5.29M
2.49%
+51.30K
+0.98%
Apr 02, 2025
UBS Financial Services, Inc.
3.87M
1.82%
+3.27M
+550.21%
Mar 31, 2025
Pale Fire Capital SE
2.59M
1.22%
+2.10M
+421.23%
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
1.84M
0.87%
-7.03K
-0.38%
Mar 31, 2025
UBS Switzerland AG
1.67M
0.79%
+324.40K
+24.15%
Mar 31, 2025
Davidson Kempner Capital Management LP
1.41M
0.67%
+464.07K
+48.88%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.33M
0.63%
-54.63K
-3.93%
Mar 31, 2025
Millennium Management LLC
1.14M
0.54%
+154.19K
+15.71%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
AdvisorShares Psychedelics ETF
9.65%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P International Small Cap ETF
0.01%
SPDR S&P Kensho New Economies Composite ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Simplify Propel Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Avantis US Equity ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
查看更多
AdvisorShares Psychedelics ETF
占比9.65%
Invesco NASDAQ Future Gen 200 ETF
占比0.43%
SPDR S&P International Small Cap ETF
占比0.01%
SPDR S&P Kensho New Economies Composite ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
Simplify Propel Opportunities ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
Avantis US Equity ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
